NEW ERA AGRICULTURE MAGAZINE

3d Bioprinting: Where Technology Meets Biology

*Astha Deshmukh and Yashwee Shrivastava

Abstract:

3D bioprinting is an innovative technology at the intersection of engineering, biology, and material science, revolutionizing the field of regenerative medicine. This additive manufacturing process enables the creation of complex, three-dimensional structures that closely mimic human tissues by incorporating living cells with biocompatible materials. Unlike traditional 3D printing, which lacks biological components, 3D bioprinting leverages the unique properties of bioinks composed of cells and biomaterials to fabricate functional tissue constructs suitable for various biomedical applications, including tissue engineering, drug delivery, and cancer therapies. The technology encompasses a range of fabrication techniques, such as extrusion-based, inkjet, and laser-assisted bioprinting, each with distinct advantages and challenges. These methods allow for precise control over the spatial arrangement of different cell types and the microenvironment, essential for maintaining cell viability and functionality. Despite its potential, 3D bioprinting faces several hurdles, including material selection, scalability, regularity hurdles and the integration of vascular networks within printed tissues. As the field continues to evolve, 3D bioprinting is poised to significantly impact personalized medicine and regenerative therapies, offering hope for more effective treatments and improved patient outcomes.

1. Introduction:

The advent of 3D printing technology marks a significant milestone in the early 21st century; it was initially employed predominantly within the realms of architecture, industrial applications and jewellery (Liu et al., 2024). In recent years, however, the domain of three-dimensional (3D) bioprinting has garnered considerable attention within tissue engineering, primarily because of its potential to fabricate intricate structures utilising biopolymers, bioactive molecules and live cells to regenerate defective tissues (Cavallo et al., 2023). This innovative technique of 3D bioprinting

Astha Deshmukh and Yashwee Shrivastava

M.F.Sc., Aquatic Animal Health Management,

ICAR-Central Institute of Fisheries Education

intriguingly merges the complexities inherent in biological systems with the precision offered by advanced printing technologies (Pasanaphong et al., 2024). Essentially, 3D bioprinting serves as a method to construct living cell-based constructs either with or without a carrier material through a meticulous layer-by-layer approach (Ji, S. and Guvendiren, M., 2017). Consequently, patient-specific constructs or implants, characterised by hierarchical organization and elevated resolution, can be readily fabricated by employing medical imaging or computer-aided design, thereby replicating the intricate geometries and irregular shapes found in native tissues (Mirshafiei et al., 2024). Furthermore, additive manufacturing (AM) technologies have been instrumental in generating bioengineered 3D structures that aim to mimic the biological and functional complexity of native tissues. The printable substance, referred to as 'bioink', integrates biomaterial ink with cells or cell-derived bioactive constituents that are indispensable for tissue regeneration (Kara Özenler A. et al., 2023). The predominant types of bioinks encompass cell-laden hydrogels, decellularized Extra Cellular Matrix (ECM)-based formulations and cell suspensions. Customization and specific to individual patients, on-demand manufacturing, heightened structural intricacy, affordability and efficiency represent several of the significant benefits associated with 3D printing, thus rendering it particularly appealing for medical applications (Ji, S. and Guvendiren, M., 2017). However, the complexities inherent in bioink formulation and tissue compatibility pose challenges that necessitate further exploration.

2. 3D Bioprinting Techniques

- **Fused Deposition Modeling (FDM):** This is among the oldest techniques of the AM technologies. According to the principle of printing with the feed of a thermoplastic polymer into the liquefier and hence extrusion of a filament, it manufactures the melted thermoplastic assigned as the support for bioinks (Vanaei et al., 2021).
- **Stereolithography (SL):** A high-printing-quality technique was developed in the 19th century, which is based on polymerization of high-sensitive polymers. The main mechanism of this technique is based on using UV laser and a directed mirror array to stick out the light-beam on the surface of the liquid photocurable resin. The main disadvantage of SL is UV light source, in which it is deleterious to the bio-cells and causes skin cancer (Vanaei et al., 2021).
- **Inkjet Bioprinting:** Inkjet bioprinters dispense bioink in a controlled flow towards the target printing site using either

thermal or acoustic approach to force the content, flowing continuously or dropping out through the nozzle. Inkjet bioprinters have several positive benefits including easy access for reaching the bioprinting platform, high rate of processing, and low expense (Hong et al., 2018).

- **Laser-assisted bioprinting (LAB):** LAB is based on the principle of laser-induced forward transfer (LIFT). High-pressure bubbles in the thin biomaterial layer are produced by a high-energy laser pulse that ejects it onto the determined place (Hong et al., 2018).
- **Extrusion bioprinting:** Extrusion bioprinting extrudes a continuous stream of bioink onto the designed stage via a pneumatic or mechanical extrusion system. Extrusion bioprinters accept a wide range of biomaterials, including hydrogels, biocompatible copolymers, and cell spheroids, all of which have viscosities that enable them to be printed (Hong et al., 2018).

3. Application of synthetic polymers in 3D bioprinting

- **Large-scale functional tissues or organs printing:** Biofabrication through 3D printing has been the most promising technique due to its ability to deposit different types of biomaterials and cells with precision. Despite the marked progresses in 3D bioprinting for tissue engineering, the preclinical and clinical translation of 3D printed living tissues has been restricted to relatively simple tissues like cartilage, bone, and skin, which comprise fairly simple structures with a limited variety of cell types (Fang et al., 2022).
- **Disease and cancer printing models**: During the last few years, 3D in vitro disease models based on human cells have shown the potential to simulate the 3D in vivo microenvironment, reproduce the interaction between pathological cells and normal cells, and regulate cellular growth and tissue function. With proper placement of cells, active molecules, and biomaterials, 3D bioprinting is an opportunity to construct in vitro complex tumor models with highly heterogeneous microenvironments (Fang et al., 2022).
- **Printing of microphysiological systems and organ-on-a-chip:** Organ-on-a-chip offers a new way to make dynamic human physiological tissue models. A small number of tissues/cells can be isolated, cultured, manipulated, and detected in an integrated system to yield biomimetic outcomes. Typically, hundreds or thousands of cellular samples, including spheroids or multicell constructs, can be included on one chip, so multiple sets of

assay data can be obtained simultaneously more cost-efficiently and speedily than with traditional methods of animal models (Fang et al., 2022).

- **Bioprinting in space:** The emergence of the space technology industry has turned the space into a strategic high ground that all countries are fighting for. Direct consumption of animal cells through bio-3D printing promises a solution to the shortage of food during the journey across a long distance in the space (Fang et al., 2022).

4. Challenges and limitations

3D bioprinting represents a sophisticated technique for the creation of geometrically intricate models that emulate biomimetic microenvironments, particularly for purposes such as drug screening and tissue regeneration. However, the immediate clinical translation of bioprinted products poses significant challenges, primarily because of the constraints associated with fabricating large-sized complex organs, including vital structures like the liver, heart and kidney. Moreover, the suturing of 3D bioprinted vascular models to native microvasculature is inherently problematic and can result in the formation of leaky blood vessels. The necessity for high cell densities, extended printing durations (ranging from a few hours to several days) and the subsequent removal of support medium from these printed large and complex organs constitute major obstacles in the biofabrication process. Regulatory and ethical considerations play a pivotal role in the implementation of embedded bioprinting for human applications; these considerations are essential to guarantee safety, efficacy and compliance with established guidelines and moral principles. In many jurisdictions, products that are either 3D-printed or bioprinted are classified as pharmaceutical or cellular entities and they often lack specific regulations governing clinical translation and commercialization. Bioprinted products necessitate the establishment of specialized regulations and standards to facilitate seamless clinical translation and commercialization; this is crucial (Budharaju et al., 2024). However, the complexity of these requirements can pose significant challenges, because they must be rigorously adhered to. Although some progress has been made, the need for comprehensive frameworks remains paramount.

5. Summary

3D bioprinting is a transformative technology that bridges the gap between biology and engineering, offering unprecedented possibilities in regenerative medicine and personalized healthcare. Through the integration of bioinks, advanced printing techniques, and innovative applications, this technology has demonstrated its potential to fabricate functional tissues and organs, simulate complex disease models, and revolutionize drug testing. Despite its immense promise, 3D bioprinting faces significant challenges, including the development of bioinks, the integration of vascular systems, scalability, and compliance with regulatory and ethical frameworks. Addressing these hurdles requires interdisciplinary collaboration and continued research to refine techniques, improve material compatibility, and establish standardized protocols. As the field progresses, 3D bioprinting has the potential to redefine the boundaries of medical science, offering hope for more effective treatments, improved patient outcomes, and the realization of fully functional bioprinted organs. The future of 3D bioprinting is bright, and its evolution will undoubtedly mark a pivotal era in the intersection of technology and biology.

References

1. Budharaju, H., Sundaramurthi, D. and Sethuraman, S., 2024. Embedded 3D bioprinting–An emerging strategy to fabricate biomimetic & large vascularized tissue constructs. Bioactive Materials, 32, pp.356-384.
2. Cavallo, A., Al Kayal, T., Mero, A., Mezzetta, A., Pisani, A., Foffa, I., Vecoli, C., Buscemi, M., Guazzelli, L., Soldani, G. and Losi, P., 2023. Marine collagen-based bioink for 3D bioprinting of a bilayered skin model. Pharmaceutics, 15(5), p.1331.
3. Fang, Y., Guo, Y., Liu, T., Xu, R., Mao, S., Mo, X., Zhang, T., Ouyang, L., Xiong, Z. and Sun, W., 2022. Advances in 3D bioprinting. Chinese Journal of Mechanical Engineering: Additive Manufacturing Frontiers, 1(1), p.100011.
4. Hong, N., Yang, G.H., Lee, J. and Kim, G., 2018. 3D bioprinting and its in vivo applications. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 106(1), pp.444-459.
5. Ji, S. and Guvendiren, M., 2017. Recent advances in bioink design for 3D bioprinting of tissues and organs. Frontiers in bioengineering and biotechnology, 5, p.23
6. Kara Özenler A, Distler T, Tihminlioglu F, Boccaccini AR. Fish scale containing alginate dialdehyde-gelatin bioink for bone tissue engineering. Biofabrication. 2023 Feb 15;15(2). doi: 10.1088/1758-5090/acb6b7. PMID: 36706451.
7. Liu Z, Shi J, Chen L, He X, Weng Y, Zhang X, Yang DP, Yu H. 3D printing of fish-scale derived hydroxyapatite/chitosan/PCL scaffold for bone tissue engineering. Int J Biol Macromol. 2024 Aug;274(Pt

2):133172. doi: 10.1016/j.ijbiomac.2024.133172. Epub 2024 Jun 15. PMID: 38880458.

8. Mirshafiei, M., Rashedi, H., Yazdian, F., Rahdar, A. and Baino, F., 2024. Advancements in tissue and organ 3D bioprinting: Current techniques, applications, and future perspectives. Materials & Design, p.112853.

9. Pasanaphong, K., Pukasamsombut, D., Boonyagul, S., Pengpanich, S., Tawonsawatruk, T., Wilairatanarporn, D., Jantanasakulwong, K., Rachtanapun, P., Hemstapat, R., Wangtueai, S. and Tanadchangsaeng, N., 2024. Fabrication of Fish Scale-Based Gelatin Methacryloyl for 3D Bioprinting Application. Polymers, 16(3), p.418.

10. Vanaei, S., Parizi, M.S., Salemizadehparizi, F. and Vanaei, H.R., 2021. An overview on materials and techniques in 3D bioprinting toward biomedical application. Engineered Regeneration, 2, pp.1-18